Skip to main content

Table 1 Characteristics of the 42 P. aeruginosa strains from the burn unit with MDR phenotypes

From: Comparative diffusion assay to assess efficacy of topical antimicrobial agents against Pseudomonas aeruginosa in burns care

Strain

Date of isolation

Patient and/or Origin

P

E

ATB

SSD

SSDC

BetG

BetL

Sulf

Chlor

PAB03

02-2005

4

Burn wound

A

1

MDR1

15.8

14.4

17.8

18.8

43.0

19.9

PAB07

03-2005

3

Burn wound

A

1

MDR1

9.1

8.0

19.9

21.0

43.0

21.0

PAB08

03-2005

4

Burn wound

A

1

MDR1

13.9

13.0

18.7

17.6

42.0

18.6

PAB13

04-2005

1

Burn wound

A

1

MDR1

11.4

11.2

20.8

19.0

46.0

20.6

PAB14

04-2005

1

Burn wound

A

1

MDR1

12.8

11.2

21.8

18.7

47.5

20.5

PAB15

04-2005

4

Burn wound

A

1

MDR2

16.4

14.8

19.2

18.5

45.0

19.4

PAB18

05-2005

1

Burn wound

A

1

MDR1

12.0

10.2

23.0

18.6

48.0

20.4

PAB20

07-2005

8

Respiratory tract

A

1

MDR1

15.4

15.0

17.7

18.4

45.0

19.1

PAB21

07-2005

8

Respiratory tract

A

1

MDR1

14.4

13.5

17.8

17.0

44.0

20.0

PAB22

07-2005

2

Urine

A

1

MDR1

15.2

13.4

21.0

19.8

46.0

21.6

PAB23

07-2005

2

Urine

A

1

MDR1

16.5

15.1

21.8

19.1

48.0

20.5

PAB25

07-2005

8

Respiratory

A

1

MDR2

15.2

15.0

22.2

18.0

47.0

20.6

PAB26

07-2005

8

Respiratory

A

1

MDR2

14.8

15.2

18.6

18,0

49.0

19.8

PAB32

11-2006

10

Burn wound

ND

1

MDR2

14.9

14.8

19.5

18.4

44.6

19.7

PAB33

01-2007

7

Burn wound

ND

1

MDR1

11.4

11.2

21.8

19.4

43.0

19.0

PAB34

02-2007

6

Burn wound

ND

1

MDR2

11.8

12.2

20.2

16,0

44.0

17.8

PAB35

02-2007

11

Burn wound

ND

1

MDR2

11.0

11.2

23.2

17.0

46.0

20.0

PAB37

03-2007

5

Burn wound

ND

1

MDR1

12.0

12.6

22.6

18.0

45.0

20.4

PAB39

01-2007

9

Burn wound

ND

1

MDR1

14.9

13.8

18.9

19.7

44.0

20.1

PAB42

01-2007

6

Burn wound

ND

1

MDR2

10.8

11.8

18.6

17.6

48.0

17.8

PAB43

02-2007

6

Blood

ND

1

MDR2

12.2

11.5

18.1

19.8

46.5

20.4

PAB44

02-2007

11

Urine

ND

1

MDR2

12.0

11.0

17.6

15.8

45.0

17.6

PAB45

02-2007

6

Respiratory

ND

1

MDR1

10.8

11.8

18.2

17.6

46.0

18.6

PAB46

03-2007

6

Burn wound

ND

1

MDR1

10.6

11.2

17.4

18.4

44.0

20.2

PAB47

03-2007

9

Burn wound

ND

1

MDR1

15.2

15.2

19.6

19.6

45.0

21.2

PAB48

03-2007

5

Burn wound

ND

1

MDR1

11.7

11.8

19.7

17.8

44.6

18.8

PAB50

04-2007

5

Respiratory tract

ND

1

MDR1

11.6

11.2

20.4

17.3

45.0

18.6

PAB29

10-2005

12

Burn wound

A

1

MDR2

11.2

12.2

21.2

16.8

44.0

19.4

PABH01

10-2006

Trap

ND

1

MDR2

14.8

14.0

20.0

18.4

47.0

19.6

PABH02

11-2006

Endoscoscope

ND

1

MDR2

14.4

14.4

19.2

17.4

46.0

19.8

PABH03

12-2006

Endoscoscope

ND

1

MDR2

14.8

14.2

18.0

17.2

46.0

20.2

PABH04

12-2006

Endoscoscope

ND

1

MDR2

14.8

14.8

19.4

18.3

49.0

18.7

PABH05

12-2006

Faucet

ND

1

MDR2

15.2

14.6

21.0

18.6

45.0

21.2

PABH06

12-2006

Endoscoscope

ND

1

MDR2

16.2

15.6

23.6

19.6

48.0

20.6

PABH07

12-2006

Endoscoscope

ND

1

MDR2

14.0

14.4

18.0

19.0

43.0

19.2

PABH08

NP

Trap

A

1

MDR1

15.4

15.2

22.4

19.0

47.0

22.0

PABH11

NP

Trap

A

1

MDR2

11.2

12.0

21.0

15.6

42.0

19.6

PABH15

04-2007

Trap

ND

1

MDR2

16.4

15.6

19.8

17.4

43.0

19.8

PABH16

04-2007

Trap

ND

1

MDR2

17.8

16.6

21.6

18.6

47.0

20.0

PABH17

NP

Mattress

A

1

MDR1

12.2

12.6

21.0

18.9

37.5

19.4

PABH23

01-2007

Trap

ND

1

MDR1

15.2

15.2

20.4

19.2

45.0

21.0

PABH29

01-2007

Basin washing-machine

ND

1

MDR2

15.0

15.2

21.4

18.0

42.0

20.0

  1. (P) for PFGE profile; (E) for ERIC-PCR type; (ATB) for antibiotics susceptibility phenotype and AWD inhibition diameters in mm for (SSD): silver sulphadiazine, (SSDC): cerium nitrate-silver sulphadiazine, (BetG): povidone iodine gel, (BetL):povidone iodine solution, (Sulf): mafenide (Sulfamylon®), (Chlor): chlorhexidine. ND not determined.